# MLLT1

Source: https://onco.cc/targets/mllt1/  
OnCo record `mllt1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MLLT1 (MLLT1 super elongation complex subunit) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Leukaemia, Non-Hodgkin lymphoma, Wilms tumour and 1 more.

## Summary

Chromatin reader component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. Specifically recognises and binds acetylated and crotonylated histones, with a preference for histones that are crotonylated. Has a slightly higher affinity for binding histone H3 crotonylated at 'Lys-27' (H3K27cr) than 'Lys-20' (H3K9cr20).

Open Targets scores its association with cancer at 0.56 (direct and indirect evidence; datatypes literature 0.87, genetic association 0.14, somatic mutation 0.71). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Wilms' Tumour.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: MLLT1 super elongation complex subunit; LTG19; YEATS1
- Tags: cancer-genes-wave
- Symbol: MLLT1
- Class: oncogene
- Biology: Chromatin reader component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. Specifically recognises and binds acetylated and crotonylated histones, with a preference for histones that are crotonylated. Has a slightly higher affinity for binding histone H3 crotonylated at 'Lys-27' (H3K27cr) than 'Lys-20' (H3K9cr20). May play a role in leukemogenic gene transcription. Acts as a key chromatin reader in acute myeloid leukaemia by recognising and binding to acetylated histones via its YEATS domain, thereby regulating oncogenic gene transcription. Location: Nucleus (UniProt). Locus 19p13.3 (HGNC).
- Where found: Leukaemia: Open Targets association 0.56 with leukaemia (MONDO_0005059); Non-Hodgkin lymphoma: Open Targets association 0.54 with non-Hodgkin lymphoma (MONDO_0018908); Wilms tumour: IntOGen driver in 1 cohort (WT); Acute lymphoblastic leukaemia: Open Targets association 0.53 with acute lymphoblastic leukaemia (MONDO_0004967)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:7134: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7134
- UniProt Q03111: https://www.uniprot.org/uniprotkb/Q03111/entry
- NCBI Gene 4298: https://www.ncbi.nlm.nih.gov/gene/4298
- Ensembl ENSG00000130382: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130382

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Wilms tumour (nephroblastoma)](https://onco.cc/cancers/wilms-tumor/)

---
JSON: https://onco.cc/api/v1/entities/mllt1.json